This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Erythropoietin
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-PERMANENT HIGH
Classic endurance-sport doping agent. Real performance benefit (3-10% in TT performance in trained cyclists per Lundby reviews). Real permanent-harm potential: at unsupervised doses pushing hematocrit >55%, thrombosis risk rises sharply (DVT, PE, stroke, MI). Multiple endurance-cyclist deaths in the late 1980s-1990s "EPO era" attributed to nocturnal cardiac events at supraphysiologic hematocrit. Strict WADA M1.1 ban with sensitive isoform-discriminating tests (urinary IEF for rhEPO vs endogenous; biological passport for hematocrit/reticulocyte tracking). For Dylan: not a biohacking tool, not a fit, hard-block on drug-tested status.
▸ Verdict change log
- 2026-06-05 — Initial verdict SKIP-PERMANENT. Thrombosis risk + WADA ban + tested-athlete status. (stub)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.